0001144204-15-028480.txt : 20150507
0001144204-15-028480.hdr.sgml : 20150507
20150507172145
ACCESSION NUMBER: 0001144204-15-028480
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150323
FILED AS OF DATE: 20150507
DATE AS OF CHANGE: 20150507
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: FL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
BUSINESS PHONE: 972-4-988-9488
MAIL ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Almon Einat Brill
CENTRAL INDEX KEY: 0001385116
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 15843066
MAIL ADDRESS:
STREET 1: C/O PROTALIX BIOTHERAPEUTICS, INC.
STREET 2: 2 SNUNIT ST, SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
4
1
v409796_4.xml
OWNERSHIP DOCUMENT
X0306
4
2015-03-23
0
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001385116
Almon Einat Brill
C/O PROTALIX BIOTHERAPEUTICS, INC.
2 SNUNIT ST, SCIENCE PARK, POB 455
CARMIEL
L3
20100
ISRAEL
0
1
0
0
SVP, Product Development
Stock Options (Right to Buy)
1.72
2015-03-23
4
A
0
250000
0
A
2025-03-23
Common Stock
250000
250000
D
25% of the shares of common stock underlying the stock options shall vest on the first one-year anniversary of the date of grant and the remaining 75% of the shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing on such anniversary. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
Does not include options to purchase 311,272 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018 and options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020.
/s/ Yossi Maimon, POA
2015-05-07